Weekly Digest – February 2026 Weekly Digest – February 2026 16 February 2026: Novartis Pluvicto (lutetium (177Lu) vipivotide tetraxetan) receives MHRA authorisation for new indication for eligible patients with PSMA‑positive metastatic castration‑resistant prostate cancer Novartis announced that the UK Medicines […]
Contact:
info@ciscientists.com
+1-908-212-7484
Optimal Dose
For a subscription, please provide your email id